Citations

Clear

4610 citation(s) found for "Lu, Brian".

Use of a Mixed Reality Headset for Full-Endoscopic Uniportal Interlaminar Resection of a Lumbar Facet Cyst: 2-Dimensional Operative Video
Bathini, Abhijith R., Dubey, Anwesha, Anastasi, Katherine D., Carlson, Brian, Parker, Jonathon J. , Fonseca, Rafael, Porche, Ken, Krishna, Chandan, Bendok, Bernard R., Bathini, Abhijith , Bathini, Abhijith R , Anastasi, Katherine, Bakhsheshian, Joshua , Fonseca, Rafaël , Krishna, Chandan , Bendok, Bernard R.

Mayo Clinic

Operative Neurosurgery | February 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/ons.0000000000001949 | PMID 41705978 Get It

Risk Factors for Surgical Revision Following Ventricular Shunt Placement for Idiopathic Normal Pressure Hydrocephalus
Hamouda, Abdelrahman, Kumar, Rahul , Pennington, Zach, Naylor, Ryan M. , McQuinn, Michelle W., Potes, Maria Astudillo , Jusué-Torres, Ignacio, Loomis, Erica, Kim, Brian D. , Heller, Stephanie F. , Ballinger, Beth A. , Graff-Radford, Jonathan, Jones, D. Richard, Cutsforth-Gregory, Jeremy K., Cogswell, Petrice M., Rinaldo, Lorenzo , Meyer, Frederic B., Elder, Benjamin D., Pennington, Zach , Astudillo Potes, Maria D, Loomis, Erica A, Pennington, Zach , Kumar, Rahul , Hamouda, Abdelrahman M. , Jusué-Torres, Ignacio , Graff‐Radford, Jonathan , Jones, David T. , Cutsforth‐Gregory, Jeremy K. , Cogswell, Petrice M. , Elder, Benjamin D.

Mayo Clinic

Operative Neurosurgery | February 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/ons.0000000000001964 | PMID 41705955 Get It

BACKGROUND AND OBJECTIVES: Ventriculoperitoneal shunt (VPS) placement is a common treatment for idiopathic normal pressure hydrocephalus (iNPH), but patients may require VPS revision. This study aims to evaluate the effectiveness of a standardized VPS placement protocol by comparing indications and rates of shunt revision compared with a historical institutional cohort. METHODS: All patients treated with VPS for “suspected” iNPH at a tertiary care center between January 2000 and January 2023 were retrospectively reviewed and divided into temporally distinct historical (before 2017) and standardized (after 2017) cohorts. Cumulative incidence and timing of VPS revision were compared using competing risks analyses. RESULTS: A total of 561 patients (median age 75.0 years) were identified with 324 (57.8%) in the historical and 237 (42.2%) in the standardized cohorts. Significant variations in surgical technique and shunt hardware were noted between the cohorts. With a median follow-up of 11.4 months for historical and 12.4 months for standardized cohort, shunt revisions occurred in 19.4% and 8.4% of patients in the historical and standardized cohorts, respectively ( P < .001). Revision indications also varied significantly with lower rates of overdrainage ( P < .001), infection ( P < .001), and proximal malfunction ( P = .042) but higher rate of distal malfunction ( P = .03) in the standardized cohort. Notably, no infections were noted in the standardized cohort. CONCLUSION: Risk of shunt revision among iNPH patients may be associated with modifiable factors related to surgical technique and shunt hardware selection. Importantly, no short-term complications such as hemorrhage, infection, or catheter malposition were observed with the standardized protocol. Development and refinement of standardized shunt protocols for iNPH patients should be commonplace to facilitate tracking, identification, and modification of modifiable technical risk factors.
Ethical dilemmas in the use of artificial intelligence in transfusion medicine
Seheult, Jansen N. , Malone, Jay R. , Yazer, Mark, Malik, Momin , Yazer, Mark H , Seheult, Jansen N , Jackson, Brian R. , Malik, Momin M. , Yazer, Mark H.

Mayo Clinic

Vox Sanguinis | February 18, 2026 | Volume: 121 | Issue: 4 | Pages: 417-429

10.1111/vox.70183 | PMID 41702690 Get It

Abstract Artificial intelligence (AI) and machine learning (ML) are beginning to enhance key workflows across blood banking (BB) and transfusion medicine (TM), including donor engagement, inventory forecasting, immunohaematology interpretation, haemovigilance and clinical decision support. These tools can extract signals from large, diverse datasets to improve efficiency, consistency and timeliness of care while enabling more proactive patient blood management. At the same time, TM is uniquely sensitive to safety and trust, so the field must pair innovation with disciplined validation and governance. This review surveys emerging applications and distils a balanced ethics and oversight framework tailored to TM and BB practice. Core elements include outcome‐focused validation and continuous monitoring; targeted fairness testing where biological or scientific plausibility suggests subgroup differences; layered transparency that distinguishes transparency, interpretability and explainability; and privacy by design with proportionate consent. We emphasize human oversight at every step: clinicians and laboratorians evaluate, monitor and troubleshoot models, perform tasks AI cannot, integrate multiple inputs to make decisions and interact with AI through guardrails such as intended‐use statements, confidence thresholds and clear override pathways. Accountability is shared across users, service directors, institutions and regulators. When implemented with these safeguards, AI can reduce preventable errors, improve resource allocation and support more equitable access to safe transfusion. The goal is principled pragmatism that protects patients and donors while enabling timely adoption of well‐validated tools.
Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer
Grier, Abby , Zhong, Mr Jeffrey, Basourakos, Spyridon P. , Singh, Parminder, Zakharia, Yousef , Lucien, Fabrice , Karnes, R. Jeffrey, Sharma, Vidit, Shah, Paras, Costello, Brian A. , Pagliaro, Lance C. , Orme, Jacob J. , Brown, Jason R., Jang, Albert , Brown, Jason R. , Singh, Parminder , Grier, Abby L , Basourakos, Spyridon , Singh, Parminder , Zakharia, Yousef , Lucien, Fabrice , Orme, Jacob J , Brown, Jason R , Jang, Albert , Calaway, Adam , Karnes, R. Jeffrey , Sharma, Vidit, Shah, Paras

Mayo Clinic

Cancers | February 16, 2026 | Volume: 18 | Issue: 4 | Pages: 623

10.3390/cancers18040623 | PMID 41749876 Get It

Non-muscle-invasive bladder cancer (NMIBC) comprises approximately 75% of new bladder cancer cases and generally carries a favorable prognosis, yet high rates of recurrence and progression necessitate close surveillance with frequent cystoscopies and repeated transurethral resections. Upfront treatment for high-risk disease is typically Bacillus Calmette-Guérin (BCG), although combinations with immune checkpoint inhibitors have reported results. Patients with BCG-unresponsive, intolerant, or refractory disease represent a subset of patients with high risk of progression, with early radical cystectomy being the standard approach for this setting. Global BCG shortages and the substantial impact of cystectomy on quality of life underscore the need for therapeutic alternatives. Over the past decade, investigational trials in immunotherapy have expanded treatment options for BCG-unresponsive NMIBC with CIS, leading to FDA approval of intravesical nadofaragene firadenovec, nogapendekin alfa-inbakicept, and systemic pembrolizumab. This narrative review summarizes developments in intravesical and systemic immunotherapies for NMIBC, highlights ongoing trials, and addresses controversies in trial design, treatment sequencing, comparative efficacy, and safety.
Comparison of Immune Cell Transfection by Different Vaccine Vectors After Intradermal Injection
Liu, J, Hinson, Destin T , Hansen, M. A, Keulen, Virginia P. Van , Parrett, Brian J. , Pease, Larry R. , Barry, Michael A., Liu, Jiani , Liu, Jiani , Barry, Michael A

Mayo Clinic

Vaccines | February 16, 2026 | Volume: 14 | Issue: 2 | Pages: 185

10.3390/vaccines14020185 | PMID 41746105 Get It

Background/Objectives: Antigen presenting cells (APCs) and immune cells have unique properties to drive or suppress immune responses. They are therefore key targets for the expression of vaccine antigens or transgene proteins. To better determine the utility of different molecular therapies to modify these cells, mRNA and DNA-based molecular therapy vectors were compared for their ability to genetically modify immune cells after intradermal injections in mice. DNA-based vectors included naked plasmid DNA, plasmid packaged in lipid nanoparticles (LNPs), and replication-defective adenovirus (Ad) vectors. mRNA delivery was mediated by packaging into LNPs like those used in COVID-19 vaccines. Methods: Each vector was used to deliver Cre recombinase into Cre reporter mice whose cells were activated to express green fluorescent protein (GFP) and firefly luciferase after Cre recombination. The mice were injected intradermally (ID) near the base of their tail at a site that drains into the inguinal lymph node. Luciferase activity was imaged in the living mice 1 or 4 days after vector injection. The animals were then euthanized, and luciferase activity was imaged in the draining inguinal lymph node. Cells were prepared from the intradermal injection site and from the draining lymph node to determine which immune cells were genetically modified by phenotyping CD45, CD3, and CD11b GFP-positive cells by flow cytometry. Given that the skin uniquely contains Langerhans dendritic cells, these CD207+ cells were also phenotyped in skin samples and in the draining lymph node. Results: In both the skin and in the draining lymph node, the rank order of luciferase and GFP activation by the vectors were: (1) Ad; (2) mRNA-LNP; (3) DNA-LNP; and (4) naked DNA. Only mRNA-LNP and Ad vectors mediated obvious luciferase activity in the living animals and in the draining lymph nodes by imaging. Notably, both vectors appeared to leak from the ID injection site and not only modify the draining lymph node but also strongly modify the livers of the mice. Naked DNA and DNA-LNP mediated detectable GFP activation in the skin and draining lymph node in some mice, but this activity was low and did not reach statistical significance when compared to PBS-treated animals. mRNA-LNPs and Ad both mediated significant Cre delivery in CD45+, CD3+, CD11b+, and CD207+ immune cells in the skin and in the lymph node, with adenovirus mediating consistently higher levels of expression in all of the tested cells. Conclusions: These data indicate that mRNA-LNP and Ad vectors mediate stronger modification of skin and lymph node immune cells after intradermal injections. Naked DNA and DNA-LNPs were markedly less potent at this activity than the other vectors. These data are consistent with the higher vaccine potency of mRNA-LNP and Ad vectors and suggest that approaches that increase targeting of immune cell subsets may have utility to increase efficacy while also reducing off-target modification of tissues like the liver.
A precise atlas of the human subcortex
Friedrich, Helen, Sahin, Ilkem Aysu , Alho, Eduardo Joaquim Lopes , Holanda, Vanessa Milanese, Brammerloh, Malte , Matthies, Cordula , Volkmann, Jens, Meyer, Garance M. , Kirilina, E. ; https://orcid.org/0000-0003-1304-4363, Pijar, Julianna , Garimella, Arun , Fox, Michael D, Friedrich, Maximilian, Edlow, Brian L., Neudorfer, Clemens, Horn, Andreas, Li, Ningfei , Edlow, Brian L , Horn, Andreas , Rajamani, Nanditha , Oxenford, Simón , Mustin, Maike, Zvarova, Patricia , Krüger, Lara, Demann, Richard, Goede, Lukas L. , Kirilina, Evgeniya P. , Volkmann, Jens , Horisawa, Shiro , Howard, Calvin, Fox, Michael , Friedrich, Maximilian, Bochtler, Anja, Edlow, Brian L. , Neudorfer, Clemens , Horn, Andreas

Mayo Clinic

No container title available | February 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.13.705755 | PMID 41726876 Get It

Abstract Clinical interventions and neuroimaging in the subcortex require anatomical definitions that exceed the resolution and anatomical detail of currently available deformable brain atlases. Here, we introduce a high-resolution human brain atlas comprising 95 manually segmented grey and white matter structures as well as 82 white matter tracts compiled from a multitude of resources including ex-vivo MRI, histology, fibre dissections, and neuroanatomy textbooks. The atlas is defined at an isotropic resolution of 100 μm and can be precisely deformed to individual subject brain anatomy. By providing precise definitions of both grey and white matter structures within and around the basal ganglia, thalamus, subthalamus, midbrain and cerebellum, the atlas provides a foundational resource for stereotactic surgery and subcortical brain imaging research, as well as for development of next-generation neuromodulation strategies.
Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II
Tzellos, Thrasyvoulos , Giamarellos‐Bourboulis, Evangelos J., Straalen, Kelsey R. van, Martorell, Antonio, Kirby, Brian, Alavi, Afsaneh, Khattri, Saakshi , Gulliver, Wayne, Sayed, Christopher J., Davis, Leah , Rolleri, Robert, Crater, Christina , Pansar, Ingrid, Zouboulis, CC, Giamarellos‐Bourboulis, Evangelos J. , Straalen, Kelsey R. van , Martorell, Antonio , Kirby, Brian , Alavi, Afsáneh , Hayama, Koremasa , Sayed, Christopher J. , Pansar, Ingrid, Lambert, Jérémy

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | February 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jdv.70356 | PMID 41689425 Get It

Abstract Background Hidradenitis suppurativa (HS) is a chronic, relapsing, debilitating skin disease characterized by deep‐seated nodules, abscesses and tunnels. Objectives To investigate the efficacy of bimekizumab using International Hidradenitis Suppurativa Severity Score System (IHS4) outcomes in patients with moderate to severe HS in the pooled BE HEARD I and II Phase 3 studies. Methods Patients received (initial/maintenance) bimekizumab 320 mg every 2 weeks (Q2W)/Q2W, bimekizumab Q2W/every 4 weeks (Q4W), bimekizumab Q4W/Q4W or placebo/bimekizumab Q2W. Change from baseline (CfB) in IHS4, IHS4 severity stages and the dichotomous IHS4‐55/75/90/100 (an improvement of at least 55%/75%/90%/100% in IHS4 from baseline) are reported to Week 48. Lesion count data by lesion type are reported to Week48. Results In total, 1014 patients were enrolled across BE HEARD I and II. At baseline, mean (standard deviation [SD]) IHS4 for bimekizumab‐treated patients ranged from 33.4 (25.4) for bimekizumab Q2W/Q2W to 36.0 (34.0) for bimekizumab Q2W/Q4W versus 30.6 (21.8) for placebo. At Week16, patients receiving bimekizumab demonstrated greater reductions in mean (SD) IHS4 from baseline, ranging from −17.2 (24.8) for bimekizumab Q4W/Q4W to −17.8 (21.1) for bimekizumab Q2W/Q2W versus −6.1 (16.3) for placebo. Proportions of patients with severe HS at baseline ranged from 83.7% (bimekizumab Q2W/Q2W) to 88.4% (bimekizumab Q2W/Q4W) and decreased by ~50% to Week48 across all treatment arms, ranging from 28.6% (placebo/bimekizumab Q2W) to 34.3% (bimekizumab Q2W/Q2W). Proportions of patients with IHS4 = 0 at Week48 ranged from 23.7% (bimekizumab Q2W/Q4W) to 26.7% (placebo/bimekizumab Q2W). At Week16, IHS4‐55, IHS4‐75, IHS4‐90 and IHS4‐100 thresholds were achieved by greater proportions of patients treated with bimekizumab versus placebo, while comparable improvements were seen across treatment arms from Week16 to Week48. At Week16, lesion counts were lower for patients treated with bimekizumab versus placebo, decreasing to comparable numbers across all groups at Week48. Conclusions Bimekizumab‐treated patients showed improvements across IHS4 outcome measures.
To Flap or Not to Flap: Conservative Treatment of Radiated Chronic Scalp Wounds With Exposed Bone
Paul, Brian, Leach, Garrison A., Holcombe, Travis C.

Mayo Clinic

Journal of Craniofacial Surgery | February 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/scs.0000000000012526 | PMID 41686084 Get It

Radiated chronic scalp wounds with exposed bone present a significant reconstructive challenge, particularly when prior attempts have failed or when further surgery is contraindicated due to patient comorbidities or preference. We retrospectively reviewed 10 patients (2014–2024) with radiated chronic scalp wounds with exposed bone who have either failed prior reconstruction, could not medically tolerate anesthesia, or declined surgery. Patients performed daily cleansing with soap and water followed by application of Aquaphor and Silvadene. Treatment duration ranged from 1 to 73 months (mean: 29.4 mo). The area of exposed bone decreased in 6 patients (60%), remained stable in 1 (10%), and increased in 3 (30%). Three of 7 patients with wound improvement (30%) achieved complete healing. Two of 3 patients with wound progression deceased of unrelated causes. To our knowledge, no major complications occurred. These findings support wound care as a safe, and often effective, treatment when larger reconstruction is not feasible.
Bloating and Breath Tests: A Pragmatic Approach
Lacy, Brian E., Cangemi, David J. , Lacy, Brian E. , Brenner, Darren M.

Mayo Clinic

American Journal of Gastroenterology | February 13, 2026 | Volume: 121 | Issue: 8 | Pages: 1789-1795

10.14309/ajg.0000000000003963 | PMID 41685789 Get It

Accurate strand-specific long-read transcript isoform discovery and quantification at bulk, single-cell, and single-nucleus resolution
Yu, Houlin , Georgescu, Christophe, Khorgade, Akanksha , Al-Eryani, Ghamdan, Bartlett, Daniel A. , Brookhart, Allison, Kockan, Can, Shin, Asa, White, Emily, Reed, Xylena, Hu, Fangle, Bromberek, Sarah, Ndayambaje, Sandra, Aryal, Sandeep , Dickson, Dennis W, Lagier-Tourenne, Clotilde, Ward, Michael, Popic, Victoria , Haas, Brian J. , AlKhafaji, Aziz M, Ward, Michael E. , Dickson, Dennis W , Ward, Michael E , Blainey, Paul C , Georgescu, C , Al‐Eryani, Ghamdan , Koçkan, Can , Webber, James T. , Shin, Asa , Reed, Xylena , Prudencio, Mercedes , Lagier‐Tourenne, Clotilde , Al’Khafaji, Aziz M.

Mayo Clinic

No container title available | February 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.12.705617 | PMID 41726986 Get It

Abstract Recent advances in long-read transcriptome sequencing enable high-throughput profiling of full-length RNA isoforms in bulk, single-cell, and single-nucleus samples. However, long-read datasets typically contain a mixture of complete and partial transcripts, leading to pervasive ambiguity in read-to-isoform assignment and complicating accurate isoform identification and quantification, particularly in the absence of reliable reference annotations. These challenges are further amplified in single-cell and single-nucleus samples, where coverage is sparse and transcriptional heterogeneity is high. Here, we present the Long Read Alignment Assembler (LRAA), a unified and versatile computational framework for isoform identification and quantification from long-read RNA sequencing data across bulk, single-cell, and single-nucleus transcriptomic samples. LRAA combines splice-graph based structural modeling with expectation maximization based optimization to probabilistically resolve ambiguous read assignments and improve isoform abundance estimation. The framework supports quantification-only, reference-guided, and fully reference-free (de novo) modes of analysis within a single methodological paradigm. We benchmarked LRAA using both simulated and genuine long-read datasets spanning sequencing standards and whole transcriptomes. Central to this evaluation is a novel benchmarking strategy based on Multiplexed Overexpression of Regulatory Factors (MORFs), which provides biologically expressed, barcoded isoforms with unambiguous read-level ground truth. Across all benchmarks, including MORFs, synthetic spike-ins, and whole-transcriptome datasets, LRAA consistently outperformed state-of-the-art methods in isoform identification accuracy, sensitivity, and expression quantification. Finally, we demonstrate the biological utility of LRAA by resolving cell-type-specific isoform usage across peripheral blood immune cell populations and by detecting a pathogenic cryptic isoform of STMN2 with associated transcriptional changes in single-nucleus RNA-seq data from frontal cortex tissue of an individual with frontotemporal dementia (FTD). Together, these results establish LRAA as a robust and general solution for resolving transcript diversity in complex biological systems, from development to disease.